Aptar數字健康與阿斯利康合作，授權用於慢性腎病檢測的人工智能算法相關的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:

動脈網

2025/05/26

by Mark Chiang由馬克·蔣Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538310414"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538310414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538310414?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-26 23:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2538310414","market":"us","top_or_hot":-1,"title":"Aptar數字健康與阿斯利康合作，授權用於慢性腎病檢測的人工智能算法相關的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:","media":"動脈網","content":"<div>\n<p>by Mark Chiang由馬克·蔣Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptar數字健康與阿斯利康合作，授權用於慢性腎病檢測的人工智能算法相關的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptar數字健康與阿斯利康合作，授權用於慢性腎病檢測的人工智能算法相關的帖子：Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-05-26 23:09</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>by Mark Chiang由馬克·蔣Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b","article_id":"2538310414","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052623120897661265&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2538310414","pubTimestamp":1748272140,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"by Mark Chiang由馬克·蔣Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence  algorithms for detecting chronic kidney disease . The collaboration grants Aptar access to AstraZeneca’s AI-driven screening technology, which is designed to identify CKD in patients more efficiently..Aptar數字健康公司與阿斯利康達成了一項許可協議，利用這家制藥公司的人工智能算法來檢測慢性腎病。此次合作使Aptar獲得了阿斯利康基於人工智能的篩查技術，該技術旨在更高效地識別患者的CKD。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","AZN":"阿斯利康","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4007":"制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4126":"金属与玻璃容器","ATR":"Aptar"},"translate_title":"Aptar Digital Health partners with AstraZeneca to license AI algorithms for chronic kidney disease detection Related posts: Aptar Digital Health Partners with AstraZeneca to License AI Algorithms for Chronic Kidney Disease Detection Related posts:","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"ATR":1},"content_text":"by Mark Chiang由馬克·蔣Share To分享到Aptar Digital Health has entered into a licensing agreement with AstraZeneca to utilize the pharmaceutical company’s artificial intelligence (AI) algorithms for detecting chronic kidney disease (CKD). The collaboration grants Aptar access to AstraZeneca’s AI-driven screening technology, which is designed to identify CKD in patients more efficiently..Aptar數字健康公司與阿斯利康達成了一項許可協議，利用這家制藥公司的人工智能（AI）算法來檢測慢性腎病（CKD）。此次合作使Aptar獲得了阿斯利康基於人工智能的篩查技術，該技術旨在更高效地識別患者的CKD。The agreement marks a step forward in leveraging advanced AI tools for healthcare applications. AstraZeneca’s algorithms are tailored to enhance early detection of CKD, a condition that often progresses without noticeable symptoms until it reaches advanced stages. By integrating this technology, Aptar aims to improve diagnostic capabilities and streamline the identification process for healthcare providers..該協議標誌着在利用先進人工智能工具用於醫療應用方面向前邁進了一步。阿斯利康的算法旨在加強慢性腎臟病（CKD）的早期檢測，這種疾病通常在無明顯症狀的情況下進展，直到晚期才會被發現。通過整合這項技術，阿普塔目標是提升診斷能力，並簡化醫療服務提供者的識別流程。Newsflash | Powered by GeneOnline AI新聞快訊 | 由GeneOnline AI提供支持Source: GO-AI-ne1來源：GO-AI-ne1Date: May 23, 2025日期：2025年5月23日Related posts:相關文章:Probiotics May Reduce Negative Feelings益生菌可能減少負面情緒DrugPatentWatch: Data Analysis Could Cut Pharma Patent Litigation Costs by 50%DrugPatentWatch：數據分析可將製藥專利訴訟成本降低50%DrugPatentWatch: Generic Drug Batch Testing and Facility Inspections are Key to Patient SafetyDrugPatentWatch：仿製藥批次檢測和設施檢查是患者安全的關鍵CDMO Pricing Study Finds Kilogram Costs Vary Widely, Ranging From $10 to $50.CDMO定價研究發現，千克成本差異很大，從10美元到50美元不等。©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版權所有。與我們合作：[email protected]電子郵件地址Author作者Mark Chiang蔣志光Related Post相關內容News Flash新聞快訊46 Percent of Advanced Liver Cancer Patients Achieve Long-Term Remission with Combined LRT-IO Therapy46%的晚期肝癌患者通過聯合LRT-IO療法實現長期緩解2025-05-262025年5月26日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}